David C Cipolla

This inventor holds 21 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 1 EPO patent, primarily in Liposomal Drug Formulations. Top assignees: Aradigm Corporation, Genentech, Inc., Grifols, S.a.. Active years: 1995-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David C Cipolla. Retrieved from https://idiyas.com/inventor/david-c-cipolla

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 12)

% Patents Active = 38.1

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 2.4

ph-index = 10

Forward Citations = 339(Granted Patents)

Location History:

San Francisco, CA (US) (1995)
Belmont, CA (US) (1998)
Danville, CA (US) (1995 - 1999)
San Ramon, CA (US) (2011 - 2021)

Company Filing History:

Oregon State University

where one patent can have more than one assignee

Years Active: 1995-2021

Loading Chart...

Areas of Expertise:

Liposomal Formulations

Inhalable Antibiotics

Ciprofloxacin

Drug Nanocrystals

Surfactant-Modified

Dual Action

Aerosolized Proteins

Human Relaxin

Concentrated Formulations

Freeze-Thaw

Immediate Release

Sustained Release

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11116765 - Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria (2021-09-14),

2. 11026941 - Concentrated, inhalable ciprofloxacin formulation (2021-06-08),

3. 10420765 - Concentrated, inhalable ciprofloxacin formulation (2019-09-24),

4. 10376508 - Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria (2019-08-13),

5. 9987227 - Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile (2018-06-05),

6. 9968555 - Liposomal formulations that form drug nanocrystals after freeze-thaw (2018-05-15),

7. 9844548 - Liposomal ciprofloxacin formulations with encapsulated ciprofloxacin nanocrystals (2017-12-19),

8. 9545401 - Concentrated, inhalable ciprofloxacin formulation (2017-01-17),

9. 9532986 - Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria (2017-01-03),

10. 9259424 - Concentrated, inhalable antibiotic formulation (2016-02-16),

11. 9078897 - Concentrated, inhalable antibiotic formulation (2015-07-14),

12. 9028864 - Concentrated, inhalable antibiotic formulation (2015-05-12),

13. 8414915 - Dual action, inhaled formulations providing both an immediate and sustained release profile (2013-04-09),

14. 8268347 - Dual action, inhaled formulations providing both an immediate and sustained release profile (2012-09-18),

15. 8119156 - Dual action, inhaled formulations providing both an immediate and sustained release profile (2012-02-21),

Title: The Innovations of David C. Cipolla: A Pioneer in Respiratory Treatment Formulations

Introduction

David C. Cipolla, located in San Ramon, CA, is a prominent inventor with a remarkable portfolio consisting of 21 patents. His innovative work primarily focuses on developing effective treatments for respiratory infections, particularly through the use of liposomal formulations.

Latest Patents

Among his latest contributions to the field are two significant patents. The first is titled "Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria - Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin." This patent describes specific liposome formulations and their delivery methods for treating respiratory tract infections and various medical conditions. The second patent, titled "Concentrated, inhalable ciprofloxacin formulation," discloses a concentrated inhalable formulation of ciprofloxacin that incorporates sodium acetate and liposome. This innovative formulation can be aerosolized and inhaled to effectively treat respiratory tract infections and other related medical conditions.

Career Highlights

Throughout his career, David has made significant contributions while working with notable companies such as Aradigm Corporation and Oregon State University. His expertise in pharmaceutical formulations has been instrumental in advancing treatment methodologies for severe respiratory infections.

Collaborations

David has collaborated with distinguished professionals in his field, including James Blanchard and Igor Gonda. These collaborations have enhanced the innovation ecosystem, propelling advancements in antibiotic delivery systems and treatment strategies.

Conclusion

David C. Cipolla stands as a noteworthy inventor whose contributions to respiratory treatment formulations have significantly impacted medical technology. With a total of 21 patents, his creative spirit and dedication to innovation continue to drive progress in the fight against respiratory infections. His work exemplifies how targeted inventions can lead to substantial advancements in healthcare.

Profile summary based on public USPTO records.